Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
OpenAI Restricts Astra AI Over Cyberattack Risks 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
BOSTON, March 07, 2018 -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that company management will present a corporate update at two investor conferences in March:
Cowen and Company 38th Annual Health Care Conference
Date: Wednesday, March 14, 2018
Time: 10:40 a.m. ET
Location: Boston, MA
17th Annual Needham Healthcare Conference
Date: Wednesday, March 28, 2018
Time: 1:30 p.m. ET
Location: New York, NY
Live audio webcasts of both presentations will be available under “Events & Presentations” in the Investors & Media section of the Company’s website at www.rhythmtx.com. Replays of the webcasts will be available on the Rhythm website for 30 days following each presentation.
About Rhythm
Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm’s lead product candidate is setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist. Rhythm also supports The Genetic Obesity Project (www.GeneticObesity.com), which is dedicated to improving the understanding of severe obesity that results from specific genetic disorders. The company is based in Boston, MA.
Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
[email protected]
